Conference Coverage

How to choose between highly effective HBV therapies


 

EXPERT ANALYSIS FROM GUILD 2018

“This [TAF] is a very good drug, a nice one to have at our disposal,” according to Dr. Terrault. “The primary reason we wanted it has to do with its safety profile.”

Its potential benefit in this regard was illustrated in a pair of multinational phase 3 clinical trials totaling nearly 1,300 patients with chronic HBV presented at the 2017 meeting of American Association for the Study of Liver Disease. After completing 96 weeks of double-blind treatment with TAF or TDF, everyone was switched to open-label TAF.

“There was a nice rebound in creatinine clearance and bone density when the switch was made from TDF to TAF,” she observed. “This is encouraging data for us, in that if you have a patient on TDF and you are concerned about renal or bone safety, you can do the switch to TAF and very quickly see some recovery in those abnormalities.”

Dr. Terrault offered the following guidance in selecting HBV therapy: For most patients with no comorbidities, monotherapy with either TAF, TDF, or entecavir is an excellent approach.

Pages

Recommended Reading

Make the Diagnosis - May 2018
MDedge Infectious Disease
ESBL-resistant bacteria spread in hospital despite strict contact precautions
MDedge Infectious Disease
FDA seeks comments on pediatric HIV product development
MDedge Infectious Disease
Persistent providers sway parents to accept HPV vaccination
MDedge Infectious Disease
Which infants with invasive bacterial infections are at risk for adverse outcomes?
MDedge Infectious Disease
Simple QI intervention helped improve HPV vaccination rates
MDedge Infectious Disease
ESBL-B before colorectal surgery ups risk of surgical site infection
MDedge Infectious Disease
FDA: PrEP indication updated to include adolescents at risk of HIV infection
MDedge Infectious Disease
The double-edged sword
MDedge Infectious Disease
HBV birth dose predicts vaccine adherence
MDedge Infectious Disease